[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555447":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":67,"collaborators":70,"id":73,"slug":43,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":43,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":43,"enrollmentInfo":81,"targetDuration":43,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":51,"whyStopped":43,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Jinzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional Treatment Group","ACTIVE_COMPARATOR","40 cases in this group to receive the standard conventional treatment (Chemotherapy + PD-1 Monoclonal Antibody)",[13],"Drug: Sintilimab",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional Treatment Combined with Leuprolide Group","EXPERIMENTAL","40 cases in this group to receive the standard conventional therapy (Chemotherapy + PD-1 Monoclonal Antibody) combined with Leuprorelin acetate, 3.75 mg",[19],"Drug: Leuprorelin acetate + Sintilimab",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Leuprorelin acetate + Sintilimab","Leuprolide, an FDA-approved GnRH agonist, reduces sex hormone production and is widely used in clinical practice.",[15],[27],"Leuprolide",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Sintilimab","PD-1 inhibitor",[9],[33],"Anti-PD-1 monoclonal",[35],{"name":36,"affiliation":5,"role":37},"Yu Zhang, Professor","PRINCIPAL_INVESTIGATOR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Wangzhi Wei","CONTACT","(86)13941620158",null,"weiwangzhi@jzmu.edu.cn",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":43},"Shuangning Yang","(86)15138955506",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University","RECRUITING","Zhengzhou","Henan","450052","China","CN",{"type":58,"coordinates":59},"Point",[60,61],113.64861,34.75778,{"lat":61,"lon":60},[64,65],{"name":46,"role":41,"phone":47,"phoneExt":43,"email":43},{"name":66,"role":37,"phone":43,"phoneExt":43,"email":43},"Liping Wang",{"type":37,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Yu Zhang","Professor",[71],{"name":72,"class":6},"The First Affiliated Hospital of Zhengzhou University","100555447",false,"NCT06512207","A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer","A Clinical Investigation on the Efficacy of Leuprorelin Acetate (Androgen Deprivation Therapy) Combined With Sintilimab (Anti-PD-1) in Advanced Lung Cancer","3.Inclusion Criteria:\n\n1. Male patients aged ≥60 years.\n2. ECOG performance status score of 0 \\~1.\n3. Expected survival time of more than 3 months.\n4. Histologically or cytologically diagnosed advanced lung cancer according to the TNM staging system established by AJCC.\n5. Patients who have not previously received any anti-PD-1 treatment.\n6. Patients with adequate bone marrow function, no significant hepatic, renal, or coagulation dysfunction as per laboratory test criteria.\n7. At least one tumor lesion meeting the following criteria:\n\n   * No prior local treatments such as radiotherapy\n   * Not biopsied during the screening period (if biopsy needed, baseline tumor assessment at least 14 days after the screening biopsy).\n   * Measurable at baseline (longest diameter of the lesion ≥10 mm; For a lymph node, short diameter ≥15 mm).\n   * If only one measurable lesion, no prior local treatments such as radiotherapy.\n8. Ability to understand and voluntarily sign a written informed consent form.\n9. Willingness to follow the study protocol and follow-up examinations.\n\nExclusion Criteria:\n\n* Exclusion of cases that do not meet the inclusion criteria","MALE","60 Years",{"count":82,"type":83},80,"ESTIMATED","INTERVENTIONAL",[86],"NA","Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.",[89,90],"NSCLC, Stage III","NSCLC, Stage IV",[92,93,94,30],"Androgen Deprivation Therapy （ADT）","Leuprorelin acetate","NSCLC","2025-09-02",{"date":97,"type":98},"2025-09-09","ACTUAL",{"date":100,"type":98},"2023-12-03",{"date":102,"type":83},"2026-06",{"name":5,"class":6},1]